期刊文献+

Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization 被引量:5

Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization
下载PDF
导出
摘要 AIM: To evaluate whether the Milan criteria are useful in patients with hepatocellular carcinoma (HCC) who received transarterial chemoembolization (TACE) before liver transplantation (LT). METHODS: Thirty-six HCC patients who fulfilled the Milan criteria after having received TACE and subsequently underwent LT were included (TACE + LT group) in the study. As controls, 21 patients who also met the Milan criteria and underwent LT without prior treatment were selected (LT group). Post-LT clinical outcomes, such as HCC recurrence, survival rate, and histologic features of explanted livers, were compared between the two groups. RESULTS: Baseline characteristics were not different between the two groups. Pre-LT maximal tumor diameter in TACE + LT group was similar to that of LT group (2.0 ± 0.6 cm vs 2.3 ± 0.9 cm; P = 0.10). Post-LT histologic findings also revealed similar maximal tumor diameter in the two groups (2.4 ± 1.4 cm vs 2.3 ± 0.9 cm; P = 0.70). Explanted livers showed similar incidence of unfavorable pathologic features. The morality within 60 d after transplantation was not different between the two groups (8.3% vs 9.5%; P = 0.99). Post-LT 5-year survival rate (57% vs 74%; P = 0.70) and cumulative recurrence rate (8.3% vs 4.8%; P = 0.90) were not significantly different between the two groups. CONCLUSION: The Milan criteria are still a useful selec- tion criteria showing favorable outcomes in HCC patientsreceiving TACE before LT. AIM: To evaluate whether the Milan criteria are useful in patients with hepatocellular carcinoma (HCC) who received transarterial chemoembolization (TACE) before liver transplantation (LT). METHODS: Thirty-six HCC patients who fulfilled the Milan criteria after having received TACE and subsequently underwent LT were included (TACE + LT group) in the study. As controls, 21 patients who also met the Milan criteria and underwent LT without prior treatment were selected (LT group). Post-LT clinical outcomes, such as HCC recurrence, survival rate, and histologic features of explanted livers, were compared between the two groups. RESULTS: Baseline characteristics were not different between the two groups. Pre-LT maximal tumor diameter in TACE + LT group was similar to that of LT group (2.0 ± 0.6 cm vs 2.3 ± 0.9 cm; P = 0.10). Post-LT histologic findings also revealed similar maximal tumor diameter in the two groups (2.4 ± 1.4 cm vs 2.3 ± 0.9 cm; P = 0.70). Explanted livers showed similar incidence of unfavorable pathologic features. The morality within 60 d after transplantation was not different between the two groups (8.3% vs 9.5%; P = 0.99). Post-LT 5-year survival rate (57% vs 74%; P = 0.70) and cumulative recurrence rate (8.3% vs 4.8%; P = 0.90) were not significantly different between the two groups. CONCLUSION: The Milan criteria are still a useful selection criteria showing favorable outcomes in HCC patients receiving TACE before LT.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第43期6992-6997,共6页 世界胃肠病学杂志(英文版)
关键词 Milan criteria Hepatocellular carcinoma Transarterial chemoembolization Liver transplantation 肝细胞癌 肝移植 治疗 病理机制
  • 相关文献

参考文献19

  • 1[1]Ringe B,Pichlmayr R,Wittekind C,Tusch G.Surgical treatment of hepatocellular carcinoma:experience with liver resection and transplantation in 198 patients.World J Surg 1991; 15:270-285
  • 2[2]Iwatsuki S,Starzl TE,Sheahan DG,Yokoyama I,Demetris AJ,Todo S,Tzakis AG,Van Thiel DH,Carr B,Selby R.Hepatic resection versus transplantation for hepatocellular carcinoma.Ann Surg 1991; 214:221-228; discussion 228-229
  • 3[3]Moreno P,Jaurrieta E,Figueras J,Benasco C,Rafecas A,Fabregat J,Torras J,Casanovas T,Casais L.Orthotopic liver transplantation:treatment of choice in cirrhotic patients with hepatocellular carcinoma? Transplant Proc 1995; 27:2296-2298
  • 4[4]Bismuth H,Chiche L,Adam R,Castaing D,Diamond T,Dennison A.Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients.Ann Surg 1993;218:145-151
  • 5[5]Mazzaferro V,Regalia E,Doci R,Andreola S,Pulvirenti A,Bozzetti F,Montalto F,Ammatuna M,Morabito A,Gennari L.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med 1996; 334:693-699
  • 6[6]Yao FY,Ferrell L,Bass NM,Watson JJ,Bacchetti P,Venook A,Ascher NL,Roberts JP.Liver transplantation for hepatocellular carcinoma:expansion of the tumor size limits does not adversely impact survival.Hepatology 2001; 33:1394-1403
  • 7[7]Taniguchi K,Nakata K,Karo Y,Sato Y,Hamasaki K,Tsuruta S,Nagataki S.Treatment of hepatocellular carcinoma with transcatheter arterial embolization.Analysis of prognostic factors.Cancer 1994; 73:1341-1345
  • 8[8]Llovet JM,Real MI,Montana X,Planas R,Coll S,Aponte J,Ayuso C,Sala M,Muchart J,Sola R,Rodes J,Bruix J.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial.Lancet 2002; 359:1734-1739
  • 9[9]Oldhafer KJ,Chavan A,Fruhauf NR,Flemming P,Schlitt HJ,Kubicka S,Nashan B,Weimann A,Raab R,Manns MP,Galanski M.Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma:marked tumor necrosis,but no survival benefit? J Hepatol 1998;29:953-959
  • 10[10]Graziadei IW,Sandmueller H,Waldenberger P,Koenigsrainer A,Nachbaur K,Jaschke W,Margreiter R,Vogel W.Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.Liver Transpl 2003; 9:557-563

同被引文献24

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部